Determination of Saliva Trough Levels for Monitoring Voriconazole Therapy in Immunocompromised Children and Adults
暂无分享,去创建一个
D. Niederwieser | R. Preiss | U. Bierbach | C. Michael | T. Lange | C. Mauz-Körholz | K. Frenzel | N. Basara
[1] P. Hoogerbrugge,et al. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation. , 2008, Therapeutic drug monitoring.
[2] A. I. Adams,et al. Treatment of invasive fungal infections: stability of voriconazole infusion solutions in PVC bags. , 2008, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.
[3] J. Donnelly,et al. Therapeutic Drug Monitoring of Voriconazole , 2008, Therapeutic drug monitoring.
[4] R. Preiss,et al. Determination of voriconazole in human plasma and saliva using high-performance liquid chromatography with fluorescence detection. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[5] Raoul Herbrecht,et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] Thierry Buclin,et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] E. Cantón,et al. Correlation of Neo-Sensitabs Tablet Diffusion Assay Results on Three Different Agar Media with CLSI Broth Microdilution M27-A2 and Disk Diffusion M44-A Results for Testing Susceptibilities of Candida spp. and Cryptococcus neoformans to Amphotericin B, Caspofungin, Fluconazole, Itraconazole, and Vori , 2007, Journal of Clinical Microbiology.
[8] N. Wood,et al. Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities , 2006, Journal of clinical pharmacology.
[9] C. Clancy,et al. In vitro efficacy and fungicidal activity of voriconazole againstAspergillus andFusarium species , 1998, European Journal of Clinical Microbiology and Infectious Diseases.
[10] B. Keevil,et al. Adverse reactions to voriconazole. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] M. Nakashima,et al. Pharmacokinetics of Voriconazole and Cytochrome p450 2C19 Genetic Status , 2004, Clinical pharmacology and therapeutics.
[12] Kathleen A. Boyle,et al. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature , 2004, Mycopathologia.
[13] O. Kristensen,et al. Use of saliva for monitoring oxcarbazepine therapy in epileptic patients , 2004, European Journal of Clinical Pharmacology.
[14] D. Andes,et al. In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.
[15] N. Wood,et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[16] J. Perfect,et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] N. Wood,et al. Safety of voriconazole and dose individualization. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] Richard Sylvester,et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.
[19] N. Wood,et al. Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.
[20] H. Lazarus,et al. Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study , 2002, Journal of clinical pharmacology.
[21] I. Lamster,et al. The diagnostic applications of saliva--a review. , 2002, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.
[22] E. Thiel,et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] E. Manavathu,et al. Voriconazole: A second-generation triazole. , 2001, Drugs of today.
[24] E. Mellado,et al. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. , 1998, The Journal of antimicrobial chemotherapy.
[25] M. Rinaldi,et al. In vitro activity of voriconazole against selected fungi. , 1998, Medical mycology.
[26] A. Espinel-Ingroff. In Vitro Activity of the New Triazole Voriconazole (UK-109,496) against Opportunistic Filamentous and Dimorphic Fungi and Common and Emerging Yeast Pathogens , 1998, Journal of Clinical Microbiology.
[27] R. Haeckel,et al. Application of saliva for drug monitoring. An in vivo model for transmembrane transport. , 1996, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.
[28] J. Zuidema,et al. Evaluation of the Salivette as sampling device for monitoring beta-adrenoceptor blocking drugs in saliva. , 1995, Journal of chromatography. B, Biomedical applications.
[29] M. V. Miles,et al. Salivary Theophylline Monitoring: Reassessment and Clinical Considerations , 1994, Therapeutic Drug Monitoring.
[30] R. Haeckel. Factors Influencing the Saliva/Plasma Ratio of Drugs , 1993, Annals of the New York Academy of Sciences.
[31] W. Jusko,et al. Pharmacokinetic Principles of Drug Distribution in Saliva a , 1993, Annals of the New York Academy of Sciences.
[32] H. Möllmann,et al. Pharmacokinetics of prednisolone after high doses of prednisolone hemisuccinate. , 1985, Biopharmaceutics & drug disposition.
[33] J. Wood,et al. Dependence of salivary drug concentration on salivary flow rate. , 1982, Methods and Findings in Experimental and Clinical Pharmacology.
[34] J. Posti. Saliva-plasma drug concentration ratios during absorption: theoretical considerations and pharmacokinetic implications. , 1982, Pharmaceutica Acta Helvetiae.
[35] M. Danhof,et al. Therapeutic Drug Monitoring in Saliva , 1978, Clinical pharmacokinetics.